BDX · Becton Dickinson and Co
Price
Snapshot
50 fields · last close| Market Cap | $51.11B |
| P/E | 54.01 |
| Float | 274.3M |
| Beta | 0.24 |
| Volatility | 5.9% |
| Exchange | NYSE |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 82 |
| Price | 186.03 |
| Change | −0.85% |
| Prev Close | 187.62 |
| Open | 188.97 |
| Day Low | 184.91 |
| Day High | 189.47 |
| Avg Vol | 2 |
| Avg $ Vol | $316.1M |
| 52W High | 210.02 |
| 52W Low | 127.59 |
| 52W Pos | 70.9% |
| From High | −11.42% |
| From Low | +45.80% |
| Max DD 1Y | −33.00% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +0.13% |
| SMA 50 | +9.86% |
| SMA 200 | +8.44% |
| RSI (14) | 64.9 |
| Vol 30D | 24.6% |
| Vol 90D | 29.9% |
| 1Y Range | 128–210 |
| Daily bars | 862 |
| Perf Week | −0.27% |
| Perf Month | +9.94% |
| Perf Quarter | +25.45% |
| Perf Half Y | +12.27% |
| Perf Year | −1.90% |
| Perf YTD | −4.57% |
| Prev Day | −0.85% |
| Clavix | A- |
| Debt / Eq | 0.76 |
| Curr Ratio | 1.11 |
| Int Cover | 3.6× |
| FCF Margin | 18.1% |
| Rev Growth | +0.1% |
| Profit | Profitable |
| Leverage | Moderate |
| Sector rank | 7 / 47 |
What BDX does
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments.
It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems.
It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.
It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products.
The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers.
The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Clavix risk grade
regraded every trading dayBDX grades A-, 82 of 100. Steadiest on Macro Resilience (72), most exposed on Price Stability (63, mixed). 3 of the 4 weighted dimensions sit above the Health Care median. Ranks 7 of 47 in Health Care by Clavix score.
How rough the ride is
| BDX | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.24 | 0.81 |
| Volatilityannualized | 5.9% | 20.4% |
| Max drawdown, past yearworst peak-to-trough fall | −33.0% | — |
| Typical daily movemedian absolute daily change | 0.85% | — |
| Days beyond ±3%of the last 252 sessions | 156% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| BDX | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.24 | 0.81 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Moderate55% of 47 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| BDX | |
|---|---|
| 1 week | −0.3% |
| 1 month | +9.9% |
| Year to date | −4.6% |
| 1 year | −1.9% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| BDX | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 8 Jul |
| Average score0 most bearish, 100 most bullish | 61 |
| Bullish · bearisharticles above 60 · below 40 | 18 · 4 |
| Directionarticles whose tone is improving vs worsening | 18 ↑ 4 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 47 Health Care names Clavix covers; the tick is the sector median.
Growth
| BDX | |
|---|---|
| Revenue growthyear over year | +0.1% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Health Care
47 companies| Metric | BDX | Sector spread | Median |
|---|---|---|---|
| Beta | 0.24 | 0.81 | |
| Volatility | 5.9% | 20.4% | |
| P/E | 54.01 | 26.14 | |
| Debt / equity | 0.76 | 0.71 | |
| Current ratio | 1.11 | 1.58 | |
| FCF margin | 18.1% | 8.6% | |
| Interest coverage | 3.6× | 6.3× |
Recent news
most recent scored articles · the chip is the article’s score · click to openBeutel Goodman & Co Ltd. increased its holdings in Becton, Dickinson and Company (BDX) by 74.9% during the second quarter, ending the period with 1,684,640 shares. The article body is truncated and does not provide further detail on the rationale or share value.
Bank of New York Mellon Corp disclosed it bought a new position in Becton, Dickinson and Company during the second quarter, acquiring 1,634,649 shares, according to an SEC filing. The article text is cut off, so the total dollar value of the purchase is not stated.
Becton Dickinson finished enrolling patients in its PREVENT clinical trial for Phasix Mesh, a product designed to prevent hernias from forming at surgical sites after abdominal surgery. Completing enrollment moves the study closer to releasing results and potentially seeking FDA approval, which BDX says would be a first-of-its-kind product in the preventive hernia category.
BDX has finished enrolling patients in its PREVENT trial for Phasix Mesh, a study aimed at showing the device can prevent incisional hernias. Completion of enrollment moves the product one step closer to a potential FDA submission for this new use.
BD (Becton Dickinson) is recalling certain needle kits used to access bone marrow for emergency IV access, after the FDA classified the recall as its most serious type. The recall is linked to 45 serious injuries and four deaths.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| EW | Edwards Lifesciences Corp | A- | $51.75B | 51.53 | 0.84 | Compare |
| HUM | Humana Inc | B | $48.82B | 37.87 | 0.68 | Compare |
| MDLN | Medline Inc | B | $48.11B | 67.50 | 0.78 | Compare |
| CAH | Cardinal Health Inc | A- | $57.82B | 33.59 | 0.54 | Compare |
| IDXX | IDEXX Laboratories Inc | B+ | $41.70B | 36.69 | 1.57 | Compare |
| COR | Cencora Inc | B+ | $64.35B | 24.52 | 0.59 | Compare |
| BSX | Boston Scientific Corp | B | $68.04B | 18.98 | 0.59 | Compare |
| CI | Cigna Group | B+ | $75.64B | 11.64 | 0.27 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.